NP-06: a novel anti-human immunodeficiency virus polypeptide produced by a Streptomyces species. 1995

S Chokekijchai, and E Kojima, and S Anderson, and M Nomizu, and M Tanaka, and M Machida, and T Date, and K Toyota, and S Ishida, and K Watanabe
Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

From an extract of a Streptomyces culture, we identified and purified a novel compound, NP-06, which is active against human immunodeficiency virus (HIV) in vitro. Analyses indicate that NP-06 is a hydrophobic 21-mer oligopeptide, N terminally cyclized through the side chain of Asp-9, containing two intramolecular cystine linkages with a molecular weight of 2,163.4. The 50% inhibitory concentrations were 2.8 and 1.3 microM when NP-06 was tested for in vitro anti-HIV-1 activity in ATH8 cells and phytohemagglutinin-activated peripheral blood mononuclear cells, respectively, NP-06 appears to block the early stage of HIV-1 infection, most likely at the stage of virus-cell fusion.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013302 Streptomyces A genus of bacteria that form a nonfragmented aerial mycelium. Many species have been identified with some being pathogenic. This genus is responsible for producing a majority of the ANTI-BACTERIAL AGENTS of practical value.

Related Publications

S Chokekijchai, and E Kojima, and S Anderson, and M Nomizu, and M Tanaka, and M Machida, and T Date, and K Toyota, and S Ishida, and K Watanabe
October 1999, Antimicrobial agents and chemotherapy,
S Chokekijchai, and E Kojima, and S Anderson, and M Nomizu, and M Tanaka, and M Machida, and T Date, and K Toyota, and S Ishida, and K Watanabe
January 1971, Zeitschrift fur allgemeine Mikrobiologie,
S Chokekijchai, and E Kojima, and S Anderson, and M Nomizu, and M Tanaka, and M Machida, and T Date, and K Toyota, and S Ishida, and K Watanabe
March 1996, Biological & pharmaceutical bulletin,
S Chokekijchai, and E Kojima, and S Anderson, and M Nomizu, and M Tanaka, and M Machida, and T Date, and K Toyota, and S Ishida, and K Watanabe
August 1995, The Journal of antibiotics,
S Chokekijchai, and E Kojima, and S Anderson, and M Nomizu, and M Tanaka, and M Machida, and T Date, and K Toyota, and S Ishida, and K Watanabe
November 1987, The Journal of antibiotics,
S Chokekijchai, and E Kojima, and S Anderson, and M Nomizu, and M Tanaka, and M Machida, and T Date, and K Toyota, and S Ishida, and K Watanabe
June 1955, The Journal of antibiotics,
S Chokekijchai, and E Kojima, and S Anderson, and M Nomizu, and M Tanaka, and M Machida, and T Date, and K Toyota, and S Ishida, and K Watanabe
January 2018, NPJ vaccines,
S Chokekijchai, and E Kojima, and S Anderson, and M Nomizu, and M Tanaka, and M Machida, and T Date, and K Toyota, and S Ishida, and K Watanabe
January 2015, Chemistry & biodiversity,
S Chokekijchai, and E Kojima, and S Anderson, and M Nomizu, and M Tanaka, and M Machida, and T Date, and K Toyota, and S Ishida, and K Watanabe
July 1994, The Journal of antibiotics,
S Chokekijchai, and E Kojima, and S Anderson, and M Nomizu, and M Tanaka, and M Machida, and T Date, and K Toyota, and S Ishida, and K Watanabe
April 1992, The Journal of antibiotics,
Copied contents to your clipboard!